San Francisco, CA -- November 30, 2021 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma,
Inc. ("The Company") is a pioneering oncology company
dedicated to providing the financing and the tools to license,
develop, manufacture, and commercialize therapeutics. The Company
has assembled a team of executives and advisors with proven
multi-disciplinary expertise in the fields of oncology and
therapeutics with leadership to identify, negotiate and amalgamate
"best in class" research, technologies, therapeutics and delivery
mechanisms that are synergistic and collaborative. The goal is to
create value, reduce costs and increase the speed of regulatory
approval and commercialization of effective and safer cancer
drugs.
The Company's long-range strategy involves getting our licensed
products through initial phases of development and finding the
appropriate path to commercial success and value creation for our
stakeholders. In our initial phases we look to pediatrics and
orphan drug designation as the capital outlay is projected to be
significantly lower than traditional drug development programs and
there is a high need for improved therapies for rare cancers with
the potential for Oncology Pharma to positively impact these
patients worldwide. The initial drug product being developed is a
nanoemulsion of dactinomycin. Dactinomycin was approved by the FDA
more than 50 years ago but has been limited in its utility due to
severe toxic side-effects at effective doses. Oncology Pharma
believes the novel formulation currently in development can
overcome this limitation by creating a safer and potentially more
effective drug formulation. This formulation may also enable
greater accumulation of the drug at the tumor site, potentially
increasing its tumor-kill effectiveness while simultaneously
sparing healthy tissues.
Studies and research have commenced. Initial feasibility work
for this proprietary nanoemulsion of dactinomycin is currently
underway. To date, initial formulations have demonstrated a high
level of drug encapsulation and an appropriate time-release
profile. Releasing dactinomycin over time following administration
lowers the maximum concentration of available drug at any given
time. A lower drug concentration in the blood should lead to fewer
and less severe side effects, resulting in a dactinomycin
formulation that has a superior safety profile. Additional work to
characterize the prospective lead drug candidates is expected to
take several months and will include physical characterization of
the nanoparticle, analytical method validation, and assessment of
free versus bound drug in the lead-candidate formulations. Upon
successful completion of the feasibility phase of this project,
Oncology Pharma intends to submit Orphan Drug Designation requests
to regulatory agencies in the USA and Europe. Investigational New
Drug-enabling safety testing is anticipated to begin in the first
half of 2022.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California
corporation that is developing nanoparticle drug delivery
platforms, including utilization of anti-nuclear antibody (ANA) to
enable targeted drug delivery of existing drug therapies to areas
of necrosis present in virtually all solid cancer tumors.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships, and costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com